ACCESS Newswire
22 Mar 2023, 12:13 GMT+10
GOTHENBURG, SWEDEN / ACCESSWIRE / March 22, 2023 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA) Gothenburg, Sweden, March 22, 2023 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced an invitation to its industry symposium at the AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders on Friday, March 31, 2023. This is an official symposium of the International Conference on Alzheimer's and Parkinson's Diseases 2023, AD/PD™ 2023.
The IRLAB-sponsored symposium with the title The management dilemma of Parkinson's disease progression and emerging treatment approaches has a distinguished panel of leading experts that will address the challenges in managing Parkinson's. This innovative program will be chaired by Mike Ward, medical journalist, with speakers addressing the patient journey and clinical management priorities (Professor Karl Kieburtz, USA); how biomarkers may redefine our notion about Parkinson's (Dr Ken Marek, USA); the emerging treatments across the progression of the Parkinson's (Professor Joakim Tedroff, Sweden). Panel discussions will be held with opportunities to answer questions from the audience and for speakers to share key learnings from their fields. The symposium will take place on Friday, March 31 from 13:50 - 15:50 in Hall F1+F2+F3.
The International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders 2023, AD/PD™ 2023, will take place on March 28 - April 1, 2023, at Svenska Mässan Gothia Towers in Gothenburg, Sweden. More information about the congress can be found on www.adpd.kenes.com.
This session is not included in the main event CME/CPD credit.
For more information
Gunnar Olsson, CEO
Phone: +46 70 576 14 02
E-mail: [email protected]
Viktor Siewertz, CFO
Phone: +46 727 10 70 70
E-mail: [email protected]
About IRLAB
IRLAB discovers and develops novel treatments of Parkinson's disease and other CNS disorders. The company's most advanced drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), are in Phase IIb and are designed to treat some of the most difficult symptoms related to Parkinson's. In 2021, Ipsen, a specialty pharma company, acquired exclusive global rights to the development and commercialization of mesdopetam.
IRLAB has discovered and generated all its drug candidates and continues to discover innovative drug candidates for the treatment of CNS disorders through its proprietary systems biology-based Integrative Screening Process (ISP) research platform. In addition to IRLAB's strong clinical pipeline, the company is also progressing three preclinical programs, IRL942, IRL757, and IRL1117, towards Phase I studies. IRLAB is listed on Nasdaq Stockholm. More information on www.irlab.se.
Attachments
SOURCE: IRLAB Therapeutics
Get a daily dose of Cleveland Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Cleveland Star.
More InformationNEW YORK, New York -U.S. stock markets closed with broad gains on Thursday, led by strong performances in U.S. tech stocks, while European...
LONDON/STOCKHOLM: The Persson family is ramping up its investment in the H&M fashion empire, fueling renewed speculation about a potential...
PARIS, France: L'Oréal is making a fresh play in the booming premium haircare segment with a new acquisition. The French beauty conglomerate...
MENLO PARK, California: Robinhood is giving European investors a new way to tap into America's most prominent tech names — without...
NEW YORK, New York - U.S. stocks diverged on Wednesday for the second day in a row. The Standard and Poor's 500 hit a new all-time...
NEW YORK CITY, New York: The U.S. dollar continues to lose ground, weighed down by growing concerns over Washington's fiscal outlook...
Washington DC [US], July 3 (ANI): As the Expedition 73 and Axiom Mission 4 (Ax-4) crews kept up their ongoing space biology studies...
ABU DHABI, 19th June, 2025 (WAM) -- Cleveland Clinic Abu Dhabi has become the first and only research hospital in the UAE to receive...
ABU DHABI, 17th June, 2025 (WAM) -- Cleveland Clinic Abu Dhabi, part of the M42 group, has successfully introduced continuous infusion...
ABU DHABI, 9th June, 2025 (WAM) -- Cleveland Clinic Abu Dhabi has successfully performed the UAE's first robotic cytoreductive surgery...
ABU DHABI,16th May, 2025 (WAM) - Oracle Health, Cleveland Clinic, and G42 today announced a strategic partnership to develop a groundbreaking...
ABU DHABI, 6th May, 2025 (WAM) -- PureHealth and its subsidiary SEHA have partnered with the number one US children's hospital, Cincinnati...